up to 261,895 new shares can be issued upon the exercise of 90,780 share options that are still outstanding under the 'Executive Share Options' plan for staff members and consultants of the Company, ...

Weiss highlighted a 2012 Cochrane Library review that examined research and found the drug is “reasonably safe” and prolongs ...

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH ...

Non-alcoholic fatty liver disease (NAFLD) occurs when excess fat ... drug sensitivity and treatment paradigms for the affected population. Here, Dewald et al. generated liver-specific DM1 mice ...

A group of researchers at VCU Massey Comprehensive Cancer Center was awarded $13 million by the National Cancer Institute.

October is Liver Cancer Awareness Month. Liver cancer is the third-leading cause of cancer-related deaths worldwide, and the ...

Liver cancer is the sixth leading cause cancer death in the U.S. The most common type of liver cancer in adults is ...

23, 2024 — As a malignant disease of the liver cells, hepatocellular carcinoma (HCC) is one of the main causes of cancer-related deaths. While the treatment options for this aggressive type of ...

Currently, there are a few available treatment options for liver cancer, including a combination of immunotherapies and a class of drugs known as tyrosine kinase inhibitors (TKIs), but their long-term ...

A group of highly experienced researchers at VCU Massey Comprehensive Cancer Center was awarded more than $13 million through ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Liver cancer is the sixth-leading cause cancer death in the U.S. The most common type of liver cancer in adults is ...